Pediatric Idiopathic Cardiomyopathy: Challenges in Etiology and Need for Targeted Therapy

Idiopathic cardiomyopathy in children is a rare but severe condition that demonstrates high morbidity and mortality. Pediatric cardiomyopathy is etiologically multifaceted, with many presentations involving de novo genetic mutations or undiagnosed metabolic conditions, but these are not definitive, which complicates diagnosis and treatment. This review explores the limitations in identifying the etiology of pediatric idiopathic cardiomyopathy and examines the impact of these challenges on the development of targeted, pediatric therapies to improve current outcomes. A literature review was conducted, analyzing current information from clinical trials, cohort studies, and specialist consensus statements focused on pediatric cardiomyopathy etiology, treatment, and outcomes. The majority of treatments are adapted from adult studies, which show limited effectiveness in children. The absence of a standardized classification system, insufficient pharmacologic evidence, and scarce pediatric-specific trials contribute to poor prognosis and generalized treatment practices. Advancing pediatric cardiomyopathy care requires precision medicine frameworks, substantial databases on genotype-phenotype, and clinical trials developed specifically for pediatric patients. Increasing attention to pediatric research and targeted treatment strategies is crucial to improving survival and outcomes from current strategies.